Skip to content

Interaction of Apelin and Angiotensin in the Systemic Circulation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01049646
Enrollment
12
Registered
2010-01-14
Start date
2010-01-31
Completion date
2010-04-30
Last updated
2010-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renin Angiotensin System

Keywords

renin-angiotensin system, apelin, systemic haemodynamics

Brief summary

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease. Apelin improves that pumping ability of the heart and we wish to know if this action persists in the presence of increased levels of angiotensin II.

Interventions

DRUGAngiotensin II

Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.

DRUGSaline

Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.

Sponsors

University of Edinburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* \> 18 years old * Healthy volunteers

Exclusion criteria

* Lack of informed consent * Age \< 18 years, * Current involvement in other research studies, * Systolic blood pressure \>190 mmHg or \<100 mmHg * Malignant arrhythmias * Renal or hepatic failure * Haemodynamically significant aortic stenosis * Severe or significant co morbidity * Women of childbearing potential. Any regular medication * Previous history of any cardiovascular disease

Design outcomes

Primary

MeasureTime frame
Cardiac output90 mins

Secondary

MeasureTime frame
Systemic haemodynamics90mins

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026